Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery

Haematologica

Volumn 92, Issue 3, 2007, Pages 366-373

  Renda, Giulia ^a   Di Pillo, Raffaele ^a   D'Alleva, Alberto ^c   Sciartilli, Adolfo ^a   Zimarino, Marco ^a   De Candia, Erica ^c   Landolfi, Raffaele ^c   Di Giammarco, Gabriele ^a,b   Calafiore, Antonio ^a,b   De Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c Chieti C/o Ospedale S Camillo de Lellis ^*

Author keywords

Bleeding; Bypass surgery; Enoxaparin; Low molecular weight heparins; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; ENOXAPARIN; HEMOGLOBIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; ANTICOAGULANT AGENT;

ADULT; AGED; ANALYZER; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG MONITORING; DRUG WITHDRAWAL; ELECTIVE SURGERY; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MALE; MEASUREMENT; OPERATION DURATION; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT DURATION; BLOOD CLOTTING TEST; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; MIDDLE AGED; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PREOPERATIVE CARE; SAMPLE SIZE; STATISTICS; THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENOXAPARIN; FACTOR XA; FEMALE; HEMOGLOBINS; HEPARIN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PREANESTHETIC MEDICATION; PREOPERATIVE CARE; SAMPLE SIZE; SURGICAL PROCEDURES, ELECTIVE; THROMBOSIS;

EID: 34247591515     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10913     Document Type: Article

References (36)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 Suppl 3:338S-400S.
2. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:340-7.
3. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004;44:2149-56.
4. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17.
5. Dacey LJ, Munoz JJ, Johnson ER, Leavitt BJ, Maloney CT, Morton JR, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000;70:1986-90.
6. Ferraris VA, Ferraris SP. 1988: Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Updated in 1995. Ann Thorac Surg 1995;59:1036-7.
7. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 2004;78:527-34.
8. Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990;15:15-20.
9. Sirvinskas E, Veikutiene A, Grybauskas P, Cimbolaityte J, Mongirdiene A, Veikutis V, et al. Influence of aspirin or heparin on platelet function and postoperative blood loss after coronary artery bypass surgery. Perfusion 2006; 21:61-6.
10. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
11. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 Suppl 3:188S-203S.
12. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
13. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89-96.
14. Clark SC, Vitale N, Zacharias J, Forty J. Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. Ann Thorac Surg 2000;69:762-4.
15. Agnelli G, Sonaglia F. Prevention of venous thromboembolism. Thromb Res 2000;97:V49-62.
16. Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost 2001;86:488-98.
17. Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 2001;102:295-309.
18. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-30.
19. Spector I, Corn M. Laboratory tests of hemostasis. The relation to hemorrhage in liver disease. Arch Intern Med 1967;119:577-82.
20. Saw J, Kereiakes DJ, Mahaffey KW, Applegate RJ, Braden GA, Brent BN, et al. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res 2003;112:301-6.
21. Moliterno DJ, Hermiller JB, Kereiakes DJ, Yow E, Applegate RJ, Braden GA, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003; 42:1132-9.
22. Diez JG, Cheong BY, O'Meallie LP, Alt EU. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. J Interv Cardiol 2004;17:307-13.
23. Ozawa T, Mammen EF. LMW heparin (anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the automated coagulation laboratory (ACL). Thromb Res 1992;66:287-98.
24. ENOX Package Insert. Available at: http://enoxtest.com/pdfs/ enoxpackageinsert.pdf. Accessed on June 30, 2003.
25. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54.
26. DeCaterina R, Giannessi D, Mazzone A, Bernini W, Lazzerini G, Maffei S, et al. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 1990;82:428-38.
27. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
28. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-40.
29. Jones HU, Muhlestein JB, Jones KW, Bair TL, Lavasani F, Sohrevardi M, et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investifation and reports. Circulation 2002;106(12 Suppl 1):I19-22.
30. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005;257:399-414.
31. Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A:157-60.
32. Fatah K, Beving H, Albage A, Ivert T, Blomback M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J 1996;17:1362-6.
33. Beving H, Zhao C, Albage A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996;7:80-4.
34. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-74.
35. Sun JC, Crowther MA, Warkentin TE, Lamy A, Teoh KH. Should aspirin be discontinued before coronary artery bypass surgery? Circulation 2005;112:e85-90.
36. Robinson KL, Marasco SF, Street AM. Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Part one: bleeding and anticoagulation issues. Heart Lung Circ 2001;10:142-53.